Provided by Tiger Trade Technology Pte. Ltd.

Aprea Therapeutics, Inc.

0.8052
+0.164925.75%
Post-market: 0.7950-0.0102-1.27%19:57 EDT
Volume:2.80M
Turnover:2.17M
Market Cap:10.14M
PE:-0.86
High:0.8500
Open:0.7042
Low:0.6801
Close:0.6403
52wk High:1.69
52wk Low:0.5480
Shares:12.59M
Float Shares:7.91M
Volume Ratio:84.25
T/O Rate:35.44%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9400
EPS(LYR):-1.9269
ROE:-46.15%
ROA:-27.73%
PB:0.26
PE(LYR):-0.42

Loading ...

Ensysce Biosciences Q2 Net Loss Widens on Higher R&D Costs

Reuters
·
Aug 14

Pyxis Oncology Q2 Loss Widens on Increased Administrative Costs

Reuters
·
Aug 13

Longeveron Q2 Net Loss Widens on Higher Legal, Clinical Trial Costs

Reuters
·
Aug 13

Aprea Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

LiveWorld Q2 Net Loss Widens on Higher Operating Costs

Reuters
·
Aug 12

Aprea Therapeutics Q2 EPS USD -0.07

THOMSON REUTERS
·
Aug 12

Aprea Therapeutics Announces Second Quarter 2026 Financial Results

THOMSON REUTERS
·
Aug 12

Top News Today/Canada: Barrick Settles Newmont Dispute, Clearing Way to List Its Gold Assets

Dow Jones
·
Aug 11

Aprea Therapeutics Inc Expected to Post a Loss of 23 Cents a Share - Earnings Preview

Reuters
·
Aug 07

Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors

TIPRANKS
·
Aug 05

Aprea Therapeutics Targets Q4 2026 Clinical Data Readout for Apr-1051 Phase 1 Acesot-1051 Trial

Reuters
·
Jul 30

Aprea Therapeutics - Acesot-1051 Enrollment Accelerating to 6-10 Patients Per Month by Q4 2026

THOMSON REUTERS
·
Jul 30

Aprea Therapeutics - Dose Escalation and Backfill Expansion Expected to Complete in Q2 2027

THOMSON REUTERS
·
Jul 30

Aprea Therapeutics - to Enroll at Least 50 Patients with Usc or Cyclin E-Overexpressing Proc

THOMSON REUTERS
·
Jul 30

Aprea Therapeutics Provides Acesot-1051 Program Update for Wee1 Inhibitor Apr-1051: Accelerating and Expanding Enrollment. Clinical Data Presentation Planned for Q4 2026

THOMSON REUTERS
·
Jul 30

Aprea Therapeutics - Advances Apr-1051 in Usc, Proc, and Combination Regimens in Head and Neck, Colorectal Cancer

THOMSON REUTERS
·
Jul 30

Aprea Therapeutics - Acesot-1051 Clinical Sites Expand from Three to Ten

THOMSON REUTERS
·
Jul 30

Aprea Therapeutics Gets NASDAQ Extension to Regain $1 Minimum Bid Price Compliance

Reuters
·
Jul 24

Aprea Therapeutics shareholders elect three Class I directors at annual meeting

Reuters
·
Jun 18

Aprea Therapeutics reports early Phase 1 activity for WEE1 inhibitor APR-1051 in advanced solid tumors at ASCO 2026

Reuters
·
Jun 01